Search Results

Efficacy of Dolutegravir Plus Lamivudine in People With TB/HIV Co‐Infection Using a Rifampicin or Rifabutin‐Based Regimen: A Retrospective Observational Case Series.

• Authors : He, Jinhong¹ (AUTHOR); He, Xiangxi¹ (AUTHOR); Xie, Xiaoxin¹ (AUTHOR)

• Source: Immunity, Inflammation & Disease. Mar2026, Vol. 14 Issue 3, p1-8. 8p.

Record details

Comparative effectiveness of dolutegravir + lamivudine versus three‐drug regimens in Swedish clinical practice: a nationwide study.

• Authors : Sörstedt, Erik^1,2 (AUTHOR) ; Nduva, George³ (AUTHOR); Månsson, Fredrik⁴ (AUTHOR)

• Source: Journal of the International AIDS Society. Mar2026, Vol. 29 Issue 3, p1-9. 9p.

Record details

The dolutegravir failure cohort: A multi-country longitudinal cohort with a randomised clinical trial of continued dolutegravir versus switch to darunavir in people with viraemia while on dolutegravir in Sub-Saharan Africa (The Ndovu Study) protocol.

• Authors : Ombajo, Loice Achieng^1,2 (AUTHOR) ; Nkuranga, Joseph^1,2 (AUTHOR); Penner, Jeremy^2,3 (AUTHOR)

• Source: PLoS ONE. 3/13/2026, Vol. 21 Issue 3, p1-14. 14p.

Record details

Effect of the Scale-Up of Dolutegravir on Retention in Care, Risk of Developing Tuberculosis and Viral Load Suppression Among People Living With HIV: Analysis of Routine HIV Clinical Data in Rural KwaZulu-Natal, South Africa (2019–23).

• Authors : Moyo, Reuben Christopher¹ (AUTHOR); Okango, Elphas² (AUTHOR); Bolton, Larisse³ (AUTHOR)

• Source: Open Forum Infectious Diseases. Apr2026, Vol. 13 Issue 4, p1-8. 8p.

Record details

Negative influence of age and low baseline CD4 on T helper cell recovery among HIV-infected individuals with fixed-dose combination of tenofovir disoproxil, lamivudine and dolutegravir

• Authors : Saravanan, Shanmugam, Author; Vignesh, Ramachandran, Author; Rengarajan, Sakthi, Author ...

Subjects: discordant; highly active antiretroviral therapy (HAART); human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS)

• Source: Frontiers in Public Health. 14

Record details

Dolutegravir Versus Dolutegravir in Combination With Tenofovir for the Treatment of HTLV-1 Infection (DOT-H)

• Authors : Carlos Brites, Full Professor - Infectious Diseases

• Source: Dolutegravir Versus Dolutegravir in Combination With Tenofovir for the Treatment of HTLV-1 Infection (DOT-H): an Open-label, Randomized,

Record details

Dolutegravir Resistance in Mozambique: Insights from a Programmatic HIV Resistance Testing Intervention in a Highly Antiretroviral Therapy-Experienced Cohort.

• Authors : Ruano, Maria¹ (AUTHOR); Flores, Antonio² (AUTHOR); Couto, Aleny³ (AUTHOR)

• Source: Infectious Disease Reports. Oct2025, Vol. 17 Issue 5, p123. 14p.

Record details

Pan-Resistant HIV-1 Drug Resistance Among Highly Treated Patients with Virological Failure on Dolutegravir-Based Antiretroviral Therapy in Zimbabwe.

• Authors : Washaya, Tendai^1,2 (AUTHOR) ; Chimukangara, Benjamin^2,3 (AUTHOR); Mayini, Justin^2,3 (AUTHOR)

• Source: Viruses (1999-4915). Oct2025, Vol. 17 Issue 10, p1348. 13p.

Record details

Nose-to-Brain Delivery of Dolutegravir via Thermoresponsive Nanostructured Lipid Carriers: Cytocompatibility and Fluorescent Biodistribution Studies.

• Authors : Taher, Salam Shanta¹ ; Al-Kinani, Khalid Kadhem¹

• Source: Journal of Nanostructures. Autumn2025, Vol. 15 Issue 4, p2227-2236. 10p.

Record details

Virological Effectiveness of Dolutegravir Plus Darunavir in People with Multi-Drug-Resistant HIV: Data from the PRESTIGIO Registry.

• Authors : Lagi, Filippo¹ (AUTHOR) ; Bellomo, Michele² (AUTHOR); Lolatto, Riccardo^2,3 (AUTHOR)

• Source: Viruses (1999-4915). Sep2025, Vol. 17 Issue 9, p1158. 11p.

Record details